PF-4708671

For research use only.

Licensed and Manufactured by Pfizer Catalog No.S2163

36 publications

PF-4708671 Chemical Structure

CAS No. 1255517-76-0

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.

Selleck's PF-4708671 has been cited by 36 publications

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.
Targets
p70 S6K1 [1]
(Cell-free assay)
160 nM
In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BHT-101 M1ny[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfGN2w2UUN3ME2wMlgzODJ2IN88US=> NITuN45USU6JRWK=
UACC-893 NUjkfnplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jUeGlEPTB;NT6xPVg5PiEQvF2= MorSV2FPT0WU
A427 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nhbGlEPTB;NT63NlU3PyEQvF2= NHLMUHFUSU6JRWK=
OCUB-M MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\sOmlEPTB;Nj62OlExOiEQvF2= NUnVfoNEW0GQR1XS
SW684 M3zDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoG2TWM2OD15LkWyNlY5KM7:TR?= NGS1Ro1USU6JRWK=
SK-LMS-1 Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnBUoozUUN3ME25MlAyOzB{IN88US=> NFL3c3NUSU6JRWK=
CP50-MEL-B NVPyNHZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TR[WlEPTB;OT6zNFQyQSEQvF2= NXnLO49DW0GQR1XS
NCI-H1651 NXTSS2t4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG4TWM2OD1zMD6wNlc3KM7:TR?= M2PpNnNCVkeHUh?=
ABC-1 MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDRbY9KSzVyPUGwMlExOzdizszN NUjlNZFpW0GQR1XS
OE19 M3rJXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLnTWM2OD1zMD6xO|M{KM7:TR?= NEDRPHNUSU6JRWK=
DSH1 Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnNTWM2OD1zMD64PFc6KM7:TR?= NVKyfI1vW0GQR1XS
SW13 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnnSXZPUUN3ME2xNU46OzF7IN88US=> MXvTRW5ITVJ?
MDA-MB-453 MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDkWnZKSzVyPUGyMlE3ODNizszN NVmwbVNIW0GQR1XS
647-V MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjsTHREUUN3ME2xNk4{PTh{IN88US=> NYTzZZpsW0GQR1XS
NCI-H2342 NVizb2F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTKV5ZJUUN3ME2xNk4{QTl3IN88US=> NXyyV2d6W0GQR1XS
LB2241-RCC NVHTem1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv2bIxKSzVyPUGyMlU4PzlizszN M1jme3NCVkeHUh?=
UACC-257 NFW0d5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHLbmJxUUN3ME2xN{41PDV|IN88US=> M4HBbXNCVkeHUh?=
NCI-H661 NFjqbnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfySGs1UUN3ME2xN{43PDR7IN88US=> MmDJV2FPT0WU
FADU M1LRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4WyU2lEPTB;MUOuOlk6OiEQvF2= MW\TRW5ITVJ?
A2780 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXG1XoFCUUN3ME2xN{45ODRzIN88US=> NVH1Um9oW0GQR1XS
NCI-H1793 NIHLS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnkcnFKSzVyPUG0MlQxQDVizszN M{\CbnNCVkeHUh?=
TE-8 MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPMTWM2OD1zNT6zOFY2KM7:TR?= MVnTRW5ITVJ?
HGC-27 NFXxNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH64Z|ZKSzVyPUG2MlE3PDRizszN MkXTV2FPT0WU
MMAC-SF M{m2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlS3TWM2OD1zNz6zO|I4KM7:TR?= M{nvOXNCVkeHUh?=
Calu-6 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfFfVhKSzVyPUG4MlE2OTNizszN MVnTRW5ITVJ?
HUTU-80 NXW1S5ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF6LkO5OVkh|ryP MlWzV2FPT0WU
SAS MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnGUGZKSzVyPUG4MlY1PTVizszN NXHZR3Y{W0GQR1XS
IST-MES1 NWLOOIM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG5TWM2OD1zOD62OVA5KM7:TR?= NWHWZZk{W0GQR1XS
C3A M1XWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXL5dmRRUUN3ME2xPE44QTF7IN88US=> NX:wcWlYW0GQR1XS
ES3 MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTF6LkizOlQh|ryP Ml:5V2FPT0WU
HSC-2 MoTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTWZlh4UUN3ME2xPU43PTRzIN88US=> NIXybopUSU6JRWK=
T47D Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTXTWM2OD1{MD6xOFg2KM7:TR?= MlfjV2FPT0WU
EW-7 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnPU3VMUUN3ME2yNE45PTh6IN88US=> MmHyV2FPT0WU
LN-405 MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MomzTWM2OD1{MD64PVY2KM7:TR?= MmC2V2FPT0WU
U031 M{jQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkCwTWM2OD1{MT60PFAzKM7:TR?= M{CyN3NCVkeHUh?=
A549 NYL2dJdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G0fmlEPTB;MkGuPFQ6OSEQvF2= M{fS[XNCVkeHUh?=
RMG-I MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH2eoZXUUN3ME2yNk4zPjZ6IN88US=> MmfVV2FPT0WU
BT-474 NVjUS4xlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJ{Lk[1OVEh|ryP Mk\mV2FPT0WU
NB69 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{frbGlEPTB;MkOuNVUzKM7:TR?= NHj4XIVUSU6JRWK=
NB7 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJ2LkG4PEDPxE1? NXy1WHh6W0GQR1XS
HCC1569 MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPuRldHUUN3ME2yOE43OTJ3IN88US=> MX3TRW5ITVJ?
MEL-JUSO NGD3VGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfPTWM2OD1{ND62PVA5KM7:TR?= MkGyV2FPT0WU
MDA-MB-175-VII MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJ3LkK1NVch|ryP MWLTRW5ITVJ?
HCC1419 NFOyW|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe5dnlKSzVyPUK1MlYxODNizszN M2L4Z3NCVkeHUh?=
Ca9-22 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJ3Lk[0N|Ih|ryP MV\TRW5ITVJ?
KGN M1vIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYe1NHlZUUN3ME2yOU44PTR5IN88US=> MlG4V2FPT0WU
LB373-MEL-D Mn\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJ4LkG5N|gh|ryP MonZV2FPT0WU
NCI-H1755 MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJ4Lki4OFEh|ryP NHu4V4pUSU6JRWK=
D-423MG MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vQWmlEPTB;MkeuNFcyPSEQvF2= NEfISohUSU6JRWK=
DK-MG NXy1RodqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJ6Lke4OFYh|ryP MVrTRW5ITVJ?
NCI-H1623 M2\pS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml71TWM2OD1{OD64N|QzKM7:TR?= M2rIbnNCVkeHUh?=
KU-19-19 NGj5OHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJ6Lkm5OUDPxE1? MULTRW5ITVJ?
C-33-A NH3BXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIC5cWxKSzVyPUK5MlIyQThizszN NXrl[WFKW0GQR1XS
SCC-4 M{D6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Hj[WlEPTB;M{CuN|M2PCEQvF2= MmjPV2FPT0WU
MG-63 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq0XVQ5UUN3ME2zNE42QTl2IN88US=> NYC3UIdUW0GQR1XS
LNCaP-Clone-FGC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTrV3hJUUN3ME2zNU41QTJzIN88US=> M{KxfnNCVkeHUh?=
CAPAN-1 MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnMTWM2OD1|MT61Nlg3KM7:TR?= MoLoV2FPT0WU
GI-ME-N Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3ITWM2OD1|MT61N|U{KM7:TR?= MXjTRW5ITVJ?
RERF-LC-MS NFvq[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrzOphbUUN3ME2zNk43PzR5IN88US=> MkHqV2FPT0WU
KLE NVH1UFlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr1TWM2OD1|Mz60N|M1KM7:TR?= MXLTRW5ITVJ?
KNS-81-FD MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXGzO2VKUUN3ME2zN{42ODB6IN88US=> MoiyV2FPT0WU
DOK MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTXUm1VUUN3ME2zOE43PjF{IN88US=> MVnTRW5ITVJ?
ACHN NUjWVYRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3LeoxKSzVyPUO1MlE2QDhizszN MkPWV2FPT0WU
KYSE-520 NHK5e4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\lTWM2OD1|NT6yN|YyKM7:TR?= M1vMWXNCVkeHUh?=
SBC-5 MlPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXWTWM2OD1|NT61NVE3KM7:TR?= MXvTRW5ITVJ?
NCI-H28 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLwTWM2OD1|NT62Olk2KM7:TR?= MYPTRW5ITVJ?
ES7 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHezVXRKSzVyPUO2MlIzPDlizszN M1HqNXNCVkeHUh?=
A172 Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTN4LkSxPFch|ryP MkLlV2FPT0WU
UM-UC-3 NHL5bHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTN5Lki3OFYh|ryP NF:0b5JUSU6JRWK=
LXF-289 MlnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmOzTWM2OD1|OD6wNFQ4KM7:TR?= NF7wcGhUSU6JRWK=
KP-4 NHG5R3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7qR|FCUUN3ME2zPE41PzN7IN88US=> Ml:xV2FPT0WU
TE-1 M1vB[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULDephmUUN3ME2zPU43PTh7IN88US=> M{G3R3NCVkeHUh?=
G-402 M4r1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPtUXZKSzVyPUSwMlA3OSEQvF2= NX62ZXZKW0GQR1XS
786-0 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfMTWM2OD12MD65NFk3KM7:TR?= M2rJVHNCVkeHUh?=
K5 M{TteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfOOZBKSzVyPUSxMlM3QDZizszN NWi0ZnBiW0GQR1XS
SK-N-DZ NInmbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPuTWM2OD12MT6zPFI{KM7:TR?= NIrwc25USU6JRWK=
OVCAR-4 NUK3fGdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTsTWM2OD12MT63OVY5KM7:TR?= MkPTV2FPT0WU
T84 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3uwUGlEPTB;NEKuNVI3OyEQvF2= MUPTRW5ITVJ?
GCIY M2PUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTR|LkC4NFMh|ryP Mkf4V2FPT0WU
BB49-HNC M1yzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXSTWM2OD12Mz6zN|Q5KM7:TR?= MUHTRW5ITVJ?
SNU-C2B NFLLWXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnYN|RKSzVyPUSzMlY1OzZizszN NFzzSnRUSU6JRWK=
TE-6 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrPOFZKSzVyPUSzMlg5QTRizszN MUnTRW5ITVJ?
23132-87 MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXDSIQ1UUN3ME20OE4zQTd6IN88US=> NWS0VY96W0GQR1XS
DMS-53 NVPUb49rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LMdWlEPTB;NESuN|M5PCEQvF2= NETJ[VdUSU6JRWK=
ONS-76 M4Lq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPVTWM2OD12ND63OlYyKM7:TR?= MlezV2FPT0WU
DMS-273 M3XSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnFc3lKSzVyPUS0Mlk1OyEQvF2= NVv4c|FjW0GQR1XS
COLO-824 M1jobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzSflBKSzVyPUS1Mlg4PzVizszN MVvTRW5ITVJ?
DMS-114 NVHuOFllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7KUVhKSzVyPUS1Mlg6OjdizszN MVrTRW5ITVJ?
YKG-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTR4LkCzOVUh|ryP M2HCZXNCVkeHUh?=
RH-18 MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\2OFFKSzVyPUS2MlM4OzNizszN MVTTRW5ITVJ?
NCI-H1355 NIfXZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTR4Lk[xPEDPxE1? MnzoV2FPT0WU
NCI-H2170 NX:1UIdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPjTWM2OD12Nz63OVg1KM7:TR?= NGq3RpdUSU6JRWK=
OC-314 M1n2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PzdWlEPTB;NEeuPFQ4QCEQvF2= MnO3V2FPT0WU
NCI-H2030 M4DL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLvTWM2OD12Nz64PVA3KM7:TR?= NGjGWpNUSU6JRWK=
22RV1 MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7VfWpKSzVyPUS3MlkxOTVizszN MWTTRW5ITVJ?
G-401 NEK3[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULZNHd1UUN3ME20PE41PDF3IN88US=> M1HvenNCVkeHUh?=
YAPC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1yzT2lEPTB;NEmuPFA4OyEQvF2= NFy1d5hUSU6JRWK=
SW1573 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnMW3pKSzVyPUWwMlI1OzVizszN M4[4cnNCVkeHUh?=
COLO-792 M{nSOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{S3OmlEPTB;NUCuOlI{PyEQvF2= MYHTRW5ITVJ?
KNS-62 MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn6bFNiUUN3ME21NE44PTB6IN88US=> NX;vZZV7W0GQR1XS
NB5 NITRZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTVzLkS1NFkh|ryP NX;sSHA2W0GQR1XS
CP66-MEL NIj6dFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPaTWM2OD13MT62OFA5KM7:TR?= NHP0PYNUSU6JRWK=
CaR-1 NUfpTlNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PYdGlEPTB;NUKuNFYxPiEQvF2= MUDTRW5ITVJ?
CAL-54 NV;xR5FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYW2fW5MUUN3ME21Nk4yOTB{IN88US=> M{HpOnNCVkeHUh?=
8305C MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T0cGlEPTB;NUKuN|E2KM7:TR?= NGP5NWdUSU6JRWK=
Calu-3 MoPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfnSIp3UUN3ME21Nk4{PzN|IN88US=> M{jmTHNCVkeHUh?=
AU565 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoOyTWM2OD13Mj61OVA6KM7:TR?= MkXSV2FPT0WU
CW-2 MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;HXIhXUUN3ME21Nk45PjV2IN88US=> NHThZVFUSU6JRWK=
BEN MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO3W4loUUN3ME21N{44QDZ{IN88US=> MXzTRW5ITVJ?
NCI-H1975 M4DJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTV|Lki5OlYh|ryP NWXwcmhmW0GQR1XS
HCT-116 NGTJdZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TVRWlEPTB;NUSuNFMzPyEQvF2= MUXTRW5ITVJ?
SH-4 NXP2VndwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u1R2lEPTB;NUSuNVM5KM7:TR?= NVHVSZVRW0GQR1XS
NCI-H1693 NVvHUpZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTV2LkKxNFMh|ryP MUnTRW5ITVJ?
BPH-1 NG\ZUpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HxSmlEPTB;NUWuNlg6OiEQvF2= NVS2NGtkW0GQR1XS
CAMA-1 Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrDSlRXUUN3ME21OU45OTF4IN88US=> NXHJUJlZW0GQR1XS
A388 NF;Sfo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\XVmpXUUN3ME21Ok4xQTh3IN88US=> M2LYVHNCVkeHUh?=
C2BBe1 NEi3W3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfrTWM2OD13Nj6yOlM1KM7:TR?= MnjEV2FPT0WU
GAMG MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3kSnR2UUN3ME21Ok42QTV3IN88US=> MY\TRW5ITVJ?
MKN28 NX;qcoplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHKVopKSzVyPUW2MlgxOTNizszN MlzvV2FPT0WU
VA-ES-BJ MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HYdmlEPTB;NU[uPFc1PSEQvF2= MXfTRW5ITVJ?
HuCCT1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTVTWM2OD13Nz6wOFkzKM7:TR?= MX;TRW5ITVJ?
BFTC-905 NX;oZo1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\vTWM2OD13Nz6yPFk5KM7:TR?= M{fqc3NCVkeHUh?=
LS-123 M3;UbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfiTIlKSzVyPUW3MlU3PjhizszN NXzCSpdFW0GQR1XS
LB996-RCC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTV6LkCyPFch|ryP M3LDdnNCVkeHUh?=
NCI-H1048 NX\PUJZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPkTWM2OD13OD6yNVg5KM7:TR?= NGm3bI1USU6JRWK=
COR-L105 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLPTWM2OD13OD63N|M4KM7:TR?= NVG0PGJ[W0GQR1XS
OVCAR-8 MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3kXWFKSzVyPUW5MlE4OTZizszN NYfhfXkxW0GQR1XS
SK-N-FI NH7UZVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTV7LkOyNFch|ryP MojtV2FPT0WU
MES-SA NETaNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3KXWpJUUN3ME21PU41PTB7IN88US=> MmeyV2FPT0WU
SCC-9 NF;iR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jEOmlEPTB;NUmuOFc2OyEQvF2= M{fUSHNCVkeHUh?=
EFO-27 NGnsU|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnHVlNKSzVyPUW5Mlk1OyEQvF2= MYDTRW5ITVJ?
GT3TKB Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HsSmlEPTB;NkCuOlA1QCEQvF2= MnPaV2FPT0WU
HCC38 M1mwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;DUmlEPTB;NkGuOFM4QSEQvF2= M3WwWHNCVkeHUh?=
MLMA M4PJO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPvOWtRUUN3ME22NU43OTZ|IN88US=> Mn;1V2FPT0WU
D-566MG MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDicFA3UUN3ME22N{42OjJ2IN88US=> MmTCV2FPT0WU
SF295 NFrqe2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDmPIFKSzVyPU[zMlY3PTVizszN MnfTV2FPT0WU
ES4 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj2TWM2OD14ND60O|E6KM7:TR?= MYfTRW5ITVJ?
CAKI-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTZ2LkW3NlEh|ryP M3;NXHNCVkeHUh?=
OAW-28 Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\IVYlKSzVyPU[0Mlk3PDdizszN NEHpSWFUSU6JRWK=
NCI-H460 MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr2VmNKSzVyPU[1MlA5QTdizszN NHfZNHRUSU6JRWK=
JAR NX\PdWJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTZ3LkW1NVYh|ryP NEXpc5hUSU6JRWK=
SNU-449 NHHGTodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTZ3Lke2NVYh|ryP NGPmNG9USU6JRWK=
D-392MG MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\lSmlEPTB;NkWuPVQ{PCEQvF2= M3rrbHNCVkeHUh?=
EW-22 NGPQd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjtT4VKSzVyPU[2MlM6PSEQvF2= NIDSS5RUSU6JRWK=
GCT NYX3ZoJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTKTWM2OD14Nz6wOFQ{KM7:TR?= NHTqdolUSU6JRWK=
NOS-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLIUoZKSzVyPU[3MlY5PjdizszN NVzQPFl3W0GQR1XS
RH-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTZ6LkW1OVkh|ryP NFvQcmtUSU6JRWK=
HuH-7 NYTWUGhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DhOWlEPTB;NkmuNVAxOiEQvF2= M37vT3NCVkeHUh?=
NUGC-3 MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXCTWM2OD15MD65OlQ1KM7:TR?= NVX6dYlZW0GQR1XS
IST-SL1 NGrxeYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPBRWx5UUN3ME23NU4zOzJ2IN88US=> NIj1cIlUSU6JRWK=
SHP-77 NX;SVpRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPoT2lKSzVyPUeyMlEyQSEQvF2= NXvNTXBFW0GQR1XS
SW1116 M3zud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jLXWlEPTB;N{KuNVQxPyEQvF2= MYjTRW5ITVJ?
LK-2 NGHsfW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TKVWlEPTB;N{KuPFYyOiEQvF2= MnTFV2FPT0WU
U-2-OS NGTRTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTd|LkG4Nlgh|ryP NFXsTpJUSU6JRWK=
KYSE-150 NIX0PZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIiyUVZKSzVyPUezMlYyOThizszN MV\TRW5ITVJ?
U251 Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTd|LkixOlgh|ryP M{\OeXNCVkeHUh?=
HT-1080 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTvTWM2OD15ND6yOVc1KM7:TR?= MXrTRW5ITVJ?
NCI-H1437 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTd2Lk[zNlYh|ryP MnzaV2FPT0WU
HPAF-II MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjqbXlKSzVyPUe0MlY1OTVizszN MUnTRW5ITVJ?
Becker MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYT1bZR5UUN3ME23OU4yOTB3IN88US=> NVHyUmEyW0GQR1XS
PANC-10-05 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlmxTWM2OD15NT6yPFY2KM7:TR?= Mo\sV2FPT0WU
TYK-nu NE\wS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTd3LkOxNFIh|ryP MVfTRW5ITVJ?
SKG-IIIa MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\Zd3VjUUN3ME23OU4{OzRzIN88US=> NELteo9USU6JRWK=
NCI-H1993 Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rueGlEPTB;N{WuO|M6PyEQvF2= NVnIUJNwW0GQR1XS
S-117 MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXoTWM2OD15NT63OVUh|ryP MorwV2FPT0WU
HuO9 MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIH0cllKSzVyPUe2MlAxPDhizszN NI\s[GpUSU6JRWK=
CAL-51 M3qy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHQbldKSzVyPUe2MlExODZizszN NYfoVmxKW0GQR1XS
BT-20 NIrJPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTd4LkKxOlgh|ryP M17PSXNCVkeHUh?=
LB831-BLC MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H2eWlEPTB;N{[uN|IyPyEQvF2= M4OxcHNCVkeHUh?=
LB1047-RCC MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTd4Lke2NVkh|ryP MWnTRW5ITVJ?
ES8 MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHkTWM2OD15OD6wNFc{KM7:TR?= NWLZelNGW0GQR1XS
UMC-11 NFTFOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1znc2lEPTB;N{iuNFg5PCEQvF2= NHPqZXFUSU6JRWK=
NCI-H226 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nMNGlEPTB;N{iuNVMyPSEQvF2= NIDENGhUSU6JRWK=
IGROV-1 M3LGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFflcXdKSzVyPUe4MlU2PSEQvF2= MoDsV2FPT0WU
BHY MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7uTWM2OD15OT61PVYh|ryP NGrMc5NUSU6JRWK=
MKN45 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXpTWM2OD16MD6zNVc1KM7:TR?= M1vpe3NCVkeHUh?=
IA-LM M4TrWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRThyLkO1NVEh|ryP MnroV2FPT0WU
WM-115 Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj2TWM2OD16MT60NVE1KM7:TR?= MkHEV2FPT0WU
VMRC-RCZ MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLkOYJVUUN3ME24NU41PDJ3IN88US=> MX3TRW5ITVJ?
NCI-H2291 NYnj[2txT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXv2c4NRUUN3ME24NU43QDR{IN88US=> M{jJZ3NCVkeHUh?=
MCF7 M17pdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTh|LkK4PVch|ryP NXjsdIN{W0GQR1XS
639-V M4nhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFmzOFZKSzVyPUi0MlYyOjlizszN MWDTRW5ITVJ?
RT4 NV;PZ5d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTh3LkK0NFMh|ryP M4HSZnNCVkeHUh?=
NCI-H2405 M1fjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zydWlEPTB;OEWuNlk6PyEQvF2= NFrW[ZJUSU6JRWK=
CAL-33 NUj3WpZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PBN2lEPTB;OEWuOlMyPSEQvF2= Mnf6V2FPT0WU
BT-549 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{POUGlEPTB;OEWuPVM5OiEQvF2= MmmyV2FPT0WU
HT-1197 M1rx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorXTWM2OD16OD6xNFc4KM7:TR?= MYfTRW5ITVJ?
G-361 NIqySIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTh6LkG0O|Qh|ryP MWjTRW5ITVJ?
LS-411N MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\wdlJKSzVyPUi5MlM{QDhizszN MYPTRW5ITVJ?
HT-144 NGjiWGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTh7LkW5PVIh|ryP Mn\BV2FPT0WU
DJM-1 M2q3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXi5O3BuUUN3ME24PU45QDR3IN88US=> MljwV2FPT0WU
CAL-12T NGfafFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXiVIJKSzVyPUmwMlc5QTVizszN NIS0bZdUSU6JRWK=
MKN7 NYHDe2Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDtfolbUUN3ME25NU4{PTVzIN88US=> M4\nWHNCVkeHUh?=
HuP-T3 M1XENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTl4LkGwNFQh|ryP MWPTRW5ITVJ?
SK-MG-1 NULOeJR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXvdWh3UUN3ME25Ok4yOzR6IN88US=> M13aV3NCVkeHUh?=
NCI-H2347 M2XGfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DqVGlEPTB;OUiuNVA1OiEQvF2= MnLXV2FPT0WU
SW872 MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml22TWM2OD1zMECuOFU3KM7:TR?= MWnTRW5ITVJ?
COLO-829 M4DjdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLXXII1UUN3ME2xNFAvPTV|IN88US=> Mmj1V2FPT0WU
MC-IXC NXHqcpJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fUSWlEPTB;MUCwMlYyPSEQvF2= NHrx[JVUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-mTOR / mTOR / p-p70S6K / p70S6K ; 

PubMed: 30423811     


As determined using Western blotting, the phospho-p70S6K (p-p70S6K) inhibitor (PF-4708671) reduced the expression of phospho-mTOR (p-mTOR) and p-p70S6K in SCC-4 and SCC-25 cells. SCC-4 and SCC-25 cells were not treated as negative control (NC) or treated with 20 µM PF-4708671 for 6 h (6 h), 12 h (12 h), 18 h (18 h), 1 day (1 d), 2 days (2 d), and 3 days (3 d). Western blot analysis was performed to examine the expression levels of p-mTOR, mTOR, p-p70S6K, p70S6K, and β-actin.

pS6 / S6 / pS6K / S6K1 / pAKT / AKT ; 

PubMed: 28626016     


Western blot of cell lysates from neurons treated with PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times.

30423811 28626016
Growth inhibition assay
Cell viability; 

PubMed: 30423811     


Inhibitory effects of various doses (0.5, 1, 2, 5, 10, 20, and 40 µM) of PF-4708671 on SCC-4 (B) and SCC-25 (C) cells were assessed using MTT assay after 72 h of treatment. Data presented are the mean and standard error of the mean of three independent experiments. * p < 0.05, ** p < 0.01, and *** p < 0.001 indicate the statistical significance of differences between cells with and without treatment. t (red ** and *** for SCC-4 and blue *, ** and *** for SCC-25).

30423811

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (76.84 mM)
Ethanol 8 mg/mL (20.49 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 390.41
Formula

C19H21F3N6

CAS No. 1255517-76-0
Storage powder
in solvent
Synonyms N/A
Smiles CCC1=CN=CN=C1N2CCN(CC2)CC3=NC4=C(N3)C=C(C=C4)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?

  • Answer:

    The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

Tags: buy PF-4708671 | PF-4708671 supplier | purchase PF-4708671 | PF-4708671 cost | PF-4708671 manufacturer | order PF-4708671 | PF-4708671 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID